Patients perspective on the safety of low-dose GCs in RA patients by country (N = 1221)
| . | Agree . | Slightly agree . | Neutral . | Slightly disagree . | Disagree . |
|---|---|---|---|---|---|
| In reference to the statement: ‘I have suffered very SAEs due to GC.’ | |||||
| All | 26 | 22 | 13 | 7 | 18 |
| Brazil | 42 | 23 | 16 | 7 | 11 |
| USA | 33 | 30 | 12 | 11 | 15 |
| UK | 18 | 19 | 16 | 8 | 39 |
| Portugal | 19 | 29 | 22 | 7 | 24 |
| Germany | 20 | 34 | 0 | 17 | 29 |
| Netherlands | 18 | 34 | 8 | 10 | 30 |
| Others | 30 | 16 | 16 | 10 | 28 |
| In reference to the statement: ‘If I take GC, I am concerned that I may suffer SAEs.’ | |||||
| USAa | 56 | 27 | 11 | 3 | 3 |
| . | Agree . | Slightly agree . | Neutral . | Slightly disagree . | Disagree . |
|---|---|---|---|---|---|
| In reference to the statement: ‘I have suffered very SAEs due to GC.’ | |||||
| All | 26 | 22 | 13 | 7 | 18 |
| Brazil | 42 | 23 | 16 | 7 | 11 |
| USA | 33 | 30 | 12 | 11 | 15 |
| UK | 18 | 19 | 16 | 8 | 39 |
| Portugal | 19 | 29 | 22 | 7 | 24 |
| Germany | 20 | 34 | 0 | 17 | 29 |
| Netherlands | 18 | 34 | 8 | 10 | 30 |
| Others | 30 | 16 | 16 | 10 | 28 |
| In reference to the statement: ‘If I take GC, I am concerned that I may suffer SAEs.’ | |||||
| USAa | 56 | 27 | 11 | 3 | 3 |
Numbers indicate percentages.
Of the 243 patients from the USA, 140 answered, through the MediGuard.org website, a slightly different question, due to local regulatory issues.
SAEs: serious adverse events.
Patients perspective on the safety of low-dose GCs in RA patients by country (N = 1221)
| . | Agree . | Slightly agree . | Neutral . | Slightly disagree . | Disagree . |
|---|---|---|---|---|---|
| In reference to the statement: ‘I have suffered very SAEs due to GC.’ | |||||
| All | 26 | 22 | 13 | 7 | 18 |
| Brazil | 42 | 23 | 16 | 7 | 11 |
| USA | 33 | 30 | 12 | 11 | 15 |
| UK | 18 | 19 | 16 | 8 | 39 |
| Portugal | 19 | 29 | 22 | 7 | 24 |
| Germany | 20 | 34 | 0 | 17 | 29 |
| Netherlands | 18 | 34 | 8 | 10 | 30 |
| Others | 30 | 16 | 16 | 10 | 28 |
| In reference to the statement: ‘If I take GC, I am concerned that I may suffer SAEs.’ | |||||
| USAa | 56 | 27 | 11 | 3 | 3 |
| . | Agree . | Slightly agree . | Neutral . | Slightly disagree . | Disagree . |
|---|---|---|---|---|---|
| In reference to the statement: ‘I have suffered very SAEs due to GC.’ | |||||
| All | 26 | 22 | 13 | 7 | 18 |
| Brazil | 42 | 23 | 16 | 7 | 11 |
| USA | 33 | 30 | 12 | 11 | 15 |
| UK | 18 | 19 | 16 | 8 | 39 |
| Portugal | 19 | 29 | 22 | 7 | 24 |
| Germany | 20 | 34 | 0 | 17 | 29 |
| Netherlands | 18 | 34 | 8 | 10 | 30 |
| Others | 30 | 16 | 16 | 10 | 28 |
| In reference to the statement: ‘If I take GC, I am concerned that I may suffer SAEs.’ | |||||
| USAa | 56 | 27 | 11 | 3 | 3 |
Numbers indicate percentages.
Of the 243 patients from the USA, 140 answered, through the MediGuard.org website, a slightly different question, due to local regulatory issues.
SAEs: serious adverse events.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
